Lung adenocarcinoma patients with epidermal growth factor receptor (EGFR)-activating mutation and genotype p16/CDKN2A homozygous deletion (n = 31) were compared with those without the deletion (n = 96) relative to their response to EGFR-TKI therapy. The deletion was associated with overall poorer response (P = .0027) and lower median PFS (5.3 months vs 10.5 months).
Patients with lung adenocarcinoma and both p16/CDKN2A homozygous deletion and activating EGFR mutations have a poor prognosis on EGFR-TKI therapy.
http://www.lungcancerjournal.info/article/S0169-5002(16)30514-1/abstract
